These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23809113)

  • 1. Future of coagulation factor replacement therapy.
    Peyvandi F; Garagiola I; Seregni S
    J Thromb Haemost; 2013 Jun; 11 Suppl 1():84-98. PubMed ID: 23809113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lasting power of new clotting proteins.
    Powell JS
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):355-63. PubMed ID: 25696879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise and challenges of bioengineered recombinant clotting factors.
    Pipe SW
    J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The More Recent History of Hemophilia Treatment.
    Franchini M; Mannucci PM
    Semin Thromb Hemost; 2022 Nov; 48(8):904-910. PubMed ID: 36108649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longer-acting clotting factor concentrates for hemophilia.
    Powell JS
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S167-75. PubMed ID: 26149018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
    Monahan PE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():33-40. PubMed ID: 26637698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges.
    Trinchero A; Sholzberg M; Matino D
    Hamostaseologie; 2020 Aug; 40(3):311-321. PubMed ID: 32726826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological rationale for new drugs in the bleeding disorders pipeline.
    Fogarty PF
    Hematology Am Soc Hematol Educ Program; 2011; 2011():397-404. PubMed ID: 22160064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
    Schaub RG
    Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Past, present and future of hemophilia: a narrative review.
    Franchini M; Mannucci PM
    Orphanet J Rare Dis; 2012 May; 7():24. PubMed ID: 22551339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular approaches for improved clotting factors for hemophilia.
    Kaufman RJ; Powell JS
    Blood; 2013 Nov; 122(22):3568-74. PubMed ID: 24065241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M; Coppola A; Tagliaferri A; Lippi G
    Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia: new protein therapeutics.
    Pipe SW
    Hematology Am Soc Hematol Educ Program; 2010; 2010():203-9. PubMed ID: 21239795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives in hemophilia treatment.
    Kessler CM
    Hematology Am Soc Hematol Educ Program; 2005; ():429-35. PubMed ID: 16304415
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.